Document is current
Any future updates will be listed below
-
Authors
Penna, G. C. https://orcid.org/0000-0003-2125-7051
Rajão, K. M. A. B. https://orcid.org/0000-0002-9361-9675
Santana, D. C. https://orcid.org/0000-0003-3463-0951
Costa, P. H. https://orcid.org/0009-0002-4737-6729
Carvalho, P. H. https://orcid.org/0009-0005-4568-0593
Gomes, G. A. https://orcid.org/0000-0003-1193-0644
Avelar, G. A. https://orcid.org/0009-0002-8665-5704
Chaves, A. L. F. https://orcid.org/0000-0002-6759-9463
Pitoia, F. https://orcid.org/0000-0002-2742-7085
- License Information
-
More Information
Article History
Received: 30 April 2024
Accepted: 7 July 2024
First Online: 30 July 2024
Compliance with ethical standards
:
: Gustavo C. Penna is a speaker and participant of the Advisory Boards for Ipsen and Knight. Fabian Pitoia is a speaker and participated in Advisory Boards for Bayer and Raffo, PI Bayer, Roche, and Novartis. Aline L. F. Chaves is a speaker and participates in Advisory Boards for Merck Serono, Merck Sharpe and Dhome, Ipsen, Knight, Bayer, Eli Lilly. Kamilla M. A. Brandão Rajão is a speaker for Knight. The other authors have no financial interests.
